Merck Management
Management criteria checks 3/4
Merck's CEO is Rob Davis, appointed in Apr 2021, has a tenure of 3.67 years. total yearly compensation is $20.27M, comprised of 7.9% salary and 92.1% bonuses, including company stock and options. directly owns 0.014% of the company’s shares, worth $34.73M. The average tenure of the management team and the board of directors is 3.9 years and 5.3 years respectively.
Key information
Rob Davis
Chief executive officer
US$20.3m
Total compensation
| CEO salary percentage | 7.9% |
| CEO tenure | 3.7yrs |
| CEO ownership | 0.01% |
| Management average tenure | 3.9yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Merck: A Low-Hanging Fruit To Pick
Dec 23Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
Dec 20
Merck: Buy Opportunity Backed By Growth
Dec 17Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To $0.81
Dec 02The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business
Nov 15Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Nov 14Merck: An Undervalued Dividend Machine
Nov 07Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat
Oct 25Market Still Lacking Some Conviction On Merck & Co., Inc. (NYSE:MRK)
Oct 15Merck Is At Support And Should Go Higher (Technical Analysis)
Oct 07Merck Appears Ready To Return To June Highs (Technical Analysis)
Sep 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$12b |
| Jun 30 2024 | n/a | n/a | US$14b |
| Mar 31 2024 | n/a | n/a | US$2b |
| Dec 31 2023 | US$20m | US$2m | US$365m |
| Sep 30 2023 | n/a | n/a | US$5b |
| Jun 30 2023 | n/a | n/a | US$3b |
| Mar 31 2023 | n/a | n/a | US$13b |
| Dec 31 2022 | US$19m | US$2m | US$15b |
| Sep 30 2022 | n/a | n/a | US$15b |
| Jun 30 2022 | n/a | n/a | US$17b |
| Mar 31 2022 | n/a | n/a | US$14b |
| Dec 31 2021 | US$14m | US$1m | US$12b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$4b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$7m | US$1m | US$5b |
| Sep 30 2020 | n/a | n/a | US$9b |
| Jun 30 2020 | n/a | n/a | US$9b |
| Mar 31 2020 | n/a | n/a | US$9b |
| Dec 31 2019 | US$8m | US$1m | US$6b |
| Sep 30 2019 | n/a | n/a | US$9b |
| Jun 30 2019 | n/a | n/a | US$9b |
| Mar 31 2019 | n/a | n/a | US$8b |
| Dec 31 2018 | US$7m | US$1m | US$6b |
| Sep 30 2018 | n/a | n/a | US$3b |
| Jun 30 2018 | n/a | n/a | US$1b |
| Mar 31 2018 | n/a | n/a | US$2b |
| Dec 31 2017 | US$6m | US$1m | US$2b |
Compensation vs Market: Rob's total compensation ($USD20.27M) is above average for companies of similar size in the US market ($USD12.86M).
Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.
CEO
Rob Davis (57 yo)
3.7yrs
Tenure
US$20,273,287
Compensation
Mr. Robert M. Davis, also known as Rob, J. D., is Chief Executive Officer and Director at Merck & Co., Inc. since July 1, 2021 and is Chairman from December 01, 2022. He serves as President at Merck & Co.,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 3.7yrs | US$20.27m | 0.014% $ 34.7m | |
| Executive VP & CFO | 3.7yrs | US$8.30m | 0.0020% $ 5.1m | |
| Executive VP & President of Merck Animal Health | 13.3yrs | US$6.20m | 0.0060% $ 15.1m | |
| Executive VP & President of Merck Manufacturing Division | 15.1yrs | US$6.24m | 0.0062% $ 15.7m | |
| Executive VP & President of Merck Research Laboratories | 7.1yrs | US$9.78m | 0.0018% $ 4.6m | |
| Senior VP of Finance | less than a year | no data | 0.00018% $ 454.0k | |
| Executive VP and Chief Information & Digital Officer | no data | no data | 0.00079% $ 2.0m | |
| Vice President of Investor Relations | 5.3yrs | no data | no data | |
| Executive VP & General Counsel | 6.7yrs | US$5.90m | 0.0012% $ 2.9m | |
| Executive VP and Chief Communications & Public Affairs Officer | 3.3yrs | no data | no data | |
| Executive VP & Chief Human Resources Officer | less than a year | no data | no data | |
| Senior VP & President Merck U.S. Human Health | 3.9yrs | no data | 0.00094% $ 2.4m |
3.9yrs
Average Tenure
56yo
Average Age
Experienced Management: MRK's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 3.4yrs | US$20.27m | 0.014% $ 34.7m | |
| Independent Director | 9.3yrs | US$400.00k | 0.000070% $ 176.5k | |
| Independent Director | 29.3yrs | US$360.00k | 0.00052% $ 1.3m | |
| Independent Lead Director | 17.1yrs | US$430.10k | 0.00020% $ 504.4k | |
| Independent Director | 4.6yrs | US$365.00k | 0.000040% $ 100.9k | |
| Independent Director | 2.6yrs | US$347.64k | 0.000040% $ 100.9k | |
| Independent Director | 6.8yrs | US$340.00k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$350.00k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$350.00k | 0.000020% $ 50.4k | |
| Independent Director | 4.8yrs | US$350.00k | 0% $ 0 | |
| Independent Director | 9.3yrs | US$380.00k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$342.36k | 0% $ 0 |
5.3yrs
Average Tenure
65.5yo
Average Age
Experienced Board: MRK's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 03:01 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Merck & Co., Inc. is covered by 61 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Fabrizio Spagna | Axia Financial Research |
| Ishan Majumdar | Baptista Research |